0001193125-12-334883.txt : 20120803 0001193125-12-334883.hdr.sgml : 20120803 20120803162034 ACCESSION NUMBER: 0001193125-12-334883 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20120801 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120803 DATE AS OF CHANGE: 20120803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 121007074 BUSINESS ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 345 PARK AVE CITY: NEW YORK STATE: NY ZIP: 10154 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 d391940d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): August 1, 2012

 

 

BRISTOL-MYERS SQUIBB COMPANY

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   1-1136   22-079-0350

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

345 Park Avenue

New York, NY, 10154

(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01. Other Events.

On August 1, 2012 Bristol-Myers Squibb Company (the “Company”) issued a press release announcing that it had suspended study drug administration in an ongoing Phase II study of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor in development for the treatment of hepatitis C. This voluntary action was taken to protect patient safety based on the emergence of a serious safety issue. The cause of the safety issue and any potential relationship to study drug are unknown at this time. The Company acquired BMS-986094 when it completed its acquisition of Inhibitex, Inc. in February 2012. The carrying value of this in-process research and development intangible asset was $1.8 billion as of June 30, 2012. The Company is assessing whether an impairment is required. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

99.1    Press release of Bristol-Myers Squibb Company dated August 1, 2012.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BRISTOL-MYERS SQUIBB COMPANY
Dated: August 3, 2012   By:  

/s/ Sandra Leung

  Name:   Sandra Leung
  Title:   General Counsel and Corporate Secretary


EXHIBIT INDEX

 

Exhibit

No.

  

Description

99.1    Press release of Bristol-Myers Squibb Company dated August 1, 2012.
EX-99.1 2 d391940dex991.htm PRESS RELEASE Press release

Exhibit 99.1

 

LOGO

Bristol-Myers Squibb Suspends Administration of Study Drug in Clinical Trial of Investigational NS5B Nucleotide for the Treatment of Hepatitis C

(Princeton, NJ, August 1, 2012) - Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Company has suspended study drug administration in an ongoing Phase II study of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor in development for the treatment of hepatitis C. This voluntary action was taken to protect patient safety based on the emergence of a serious safety issue. The cause of the safety issue and any potential relationship to study drug are unknown at this time.

With patient safety as the priority, the Company is undertaking an immediate assessment of all patients in the study and following an evaluation of the patient data, will take appropriate actions.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

# # #

 

Media:    Sonia Choi, 609-252-5132, sonia.choi@bms.com
Investors:    John Elicker, 609-252-4611, john.elicker@bms.com or Timothy Power, 609-252-7509, timothy.power@bms.com
GRAPHIC 3 g391940ex99_1.jpg GRAPHIC begin 644 g391940ex99_1.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`(@#Z`P$1``(1`0,1`?_$`+L```("`P$!`0`````` M```````(!PD%!@H"!`,!``(#`0$!`0`````````````'!`4&"`,"`1````<` M`0,#`0()"04)`````0(#!`4&!P@`$1(A$PD4(A4Q05$R,S46-E9A0B,T9!TW>Q.THBJUY$XB`I)R$NZ M3^H6]0:M"JKG^PD80M,/C3E+];9F[=N`7E?X1Q(-TC_S*#0?I-11U(U4YO*# M$8Y[I5[ER2J11UH9)I#MC0?9N8CBG5(43DMD#8ZU-[C?#W:=TF MFPU\N"#V=H+FR5?7;17D*M8J1W/U%S=RW$232@O"9([J2,1R1;E`C#D1H49)%CEAHY$;U;!UEU2E'UOHI.- M>49C8\TB&4WJFKVB=>VS,:]7I%G(/H^P42#82D/:;B[?1T0[<&:2R<$C&^T` M+JN?LE5QZ9:\B2"_.4O+NVNG*V]O&@CG=U(!25RK1Q@%E&Z,REZ^T+U(W#X: MQFDGQHQ%C9W5G&'N;F1S+;QQL&97A16224E49ML@A$=/0L>RT3U!!& ML9QB#*X3*IG\.]S^4.]S(\#$DW,4`B60[!15>)&)BCC"KWUE2A!!U?%%2L;. MQ<9.0SYM)P\S'LY:)DF:I5FDA&R+9-VQ?-5B")%6SMJL50A@]#%,`]<]30RV M\SV\ZE)XV*LIZ$,IH01]H(H==-03PW,*7-NP>"1`RL.H96%00?B"""-??_M_ M(`?E'\@!UY:]=(3<_D]X+4BVR5#=[]"6BXPQG83-?S*N776'L0#`_M/SR1LV MK=H;,R,5?LK"=0/:-Z&[#Z=,2Q\4<_O[-<@F.DALGIM>=XK<-7TV]]XR:_"@ MZ_#2SR'F+QQC;UL;)DXYKY*[DMXYKDKM^:I@CD`V_I=>GQTQ.$\ M8+IM8TVM,WOW9)NZ^Z5^KA9/VP5^[IZ'?(LYF#?"F/D5)VW1.8OJ`"'KUF>0 M\7Y!Q2\%AR&TEM;IEW*''1E]*HP)5Q]ZDC6KXWROCO+[(Y#C=W%=VJM1BA-4 M)%0'1@'0D=0&45'4=-3;U0ZT.L3#3\#8VR[VO3<1/,VSYY%N7<+),I5JWDX] M46\A'+N&*RZ23]BN42+(F$%$CAV,`#U[3VUQ:N([F-XY"H8!E*DJ>H8`@=". MH/H1Z:\+>ZMKM#):R1RQABI*,&`9>C*2":$'H1Z@^NLMUXZ]]'1HT=&C4+9_ MR,PK5[Y?WQ]V6[+R+M[FT`DJ#1J48$-2A!Z$ZS^+ MY7QS-Y*YQ&(O(+G(V87O)&V_M[B0`S"J[JJ05#%E(]P&MRT?2*-D5*GM&TFR M,:C1ZNV2>6"QR97)F$4U7=(,DW#KZ1!RN5$7+DA1,!!`OEW'L`"(0<7B\AFK M^/&8N)IK^8D(BTJQ`)H*D"M`=3\ME\;@L?+ELO,L&.A`+R-6B@D`$T!-*D?# M6OXUN>0#B.AUG3:7]ZOH,UBJK\'[!*8C`1,_C%Q$J:K=XV(Y3.8ARE M,*:A#!W*8HC)SG'\UQJ]_+L];2VM]L#;)!0[6K1A]H-"*CX@CU&HV!Y'@^46 M/YGQ^ZBN[#>4WQFH#"A*GT((!!H1Z$'T(UA]QY)X-QIA82P[UJM0RN&LDHK" MP#VV2/T19>40:G?.&;!)--9PY4;M$Q.H)2"4@"'D("8O?VP'%^0\IGDMN/6D MUW/$FYQ&*[5)H"?0"IZ#[?YM>'(N6<;XE;QW7)+R&SMY7VH9#3@] M32@Z5]1J1Z3=:MHU2KU[I$RVL-1M<6VFJ].,R.$VLK%O"^;9ZW(Z1;N`26+Z ME\R%'M^+JLO["[QEY)C[]#%>PN5=#2JL/4&A(Z?RZM(O(][9QW MUOBIS#*H9`QC1V4]:B-W60BAK\OIU]-*^\\S^,;&^?'W&7@^HC;:Q597C5@2 M*&5(VCK4$?/Z]/73E9AIE'V;/:AJF:SR%GH5\A&EBJL^V0=M492(>E$6[DK5 M^@U>MC")1*9-9,BA#`(&*`AVZP^6Q5_@\E-B,I&8LA;R%)$)!VL/45!(/\H) M!^&M]B,MC\]C(,QBI!+CKB,/&X!&Y3\:,`P/P((!!Z$:WOJOU9:.C1K$R\_` MU]-DM/S<1!I24DTAHY68DV48G(3$@82,(IB=ZN@5W)/3E$$4$Q,JH(=BE'KV M@MKBY++;1O(54LVU2U%'JQH#11\2>@^.O">ZMK4*UU)'&KN$7>P7.S;4Z<^V]6$DK$IF<;*IR5HCX>)2:KOGI*$2>G0663.!DR&+W$+<\8Y`N#/)7M)UP/<""=EVQLS5`"DTW]002H(!Z$ MC5,.5<<;/CBR7D#7FJH8I"`8P@`U^/QU_E MKQ,?BX9;B^D-%CC4N['[E4$]!U)]`.IZ:LLEE,=AK*3)9:>*VQ\0J\DC!$4> MG5F('4]`/4F@'77Q9EIE#V2A5G3\QLC*X4&Y,!E*Q9HXCI-C,1Y7"[07;8CU MNU=`E]0V.4/-,HCX]^W;MU]Y7%9#!Y&7$Y6)HNJ_5CJO2Q[Q%WWD!,Q]"CV>E2 M&#NGM2KT+]_LH&C0FJR[`&USO.BW-V"S&%;TR!?A"1S-JA(S2SAU*BFS$@)K M%9=KQZ7'<<23(LUK'D`)';87E>W4UBBAB%"QE<=UV8I$`L-7K5=*F[Y-#E.4 M218Q%O)<83%&F\)"ERXI+-/*:A!$A[*(JR2EFFI'2C:C+5:K8XG&;#GVH!1[ MK$'G[?I=9U/*W#H1HURM4]/VF5@;M1G,G*6A.D.3V5[$??T2J_62CU@<.635 M1(%^K7#WEM/G(LCBN_!-VXX'@N`/WL4:)&KQ2A5C[HV))VI`@+C:LC@[=4V; MLKR'C\N*S/TUQ`99;B.YMB?W,LKO(R30EFD[)[CQ=Z(N0AW/&A7=I-5N6*6I M)2%->6C[M=:@GA=;M=[(@>5;75E5XNX.8]>JM8I)VM;)J>1;C)2D9'E6,F\B MW$6J4I'13];A>'MB66]CAW+:&[>.*NTQ&1HP1(6H(T2NR.1Z56191U0C6`;F MXS2MCY)]CWHLXY)J;A,L:RE3$%!,KN!W)(TK1HWA:@<'5C,2TT@CW-+M0*YF M%'J6,5J>J](Q^_79JEH=X@+*V@T9.2LEG@7,K7,]LID:^BJU:JIS1W#E949! M=JH<0264SXPQW5AD9;NXO+Z5));F&(]F)T+E52-PKS)5R&8&+:H';5P.K8@C MRPDL\CBX;.VL,&QT\+Q< MN/#=1U7)"&:.M%H5`LOT32TUFG2LL*5GIH(LG3Z+FH:D6EZ!HQ_&.GT:I#2; M1%)81:J`$3EF$O3CX.2L!+$Y$,TR5,&"2@DCB9J214!*ND,A_=O&SQF*2-5;V'3R=@'T$`$!]!` M0[@(#Z"`@/H("'2_]-,GUZ'7,%P,U?".*/.KY@+WI,C!9AG=>VFNU6,>1M7D M'+.+^]+?I#IM!1,-48:1>-FSU5AY^TBW*CY)@)NW8.NK_(>'Y#S#Q_PO'XM9 M+O)R6+R,&D`+;8H`79I&`)&[U)KUUQ]XWS7&N$^1N<9/+-'9XJ*]2-2L;$+N MGN2$5(D8@';Z!:=!7T&I%^->=I*/(GY&?DE:3E?S+AMH3EJE7V:T@Q4E'1X> M30>RNC66BUM64EJ@5XY2=+-F[YNC(+FE5?%'L4PC6^4;>_;C7&?%[QR77-[8 M'>:':-RD+"DKA5DH-H9E8H!&M6ZC5IXEN\:.3\I\L))%:<#N6]@)7<=K@M,\ M,99HZD.RAU#DS,`O0ZL.S/Y:.#NQ6BH4RCZ+995]>82ZS3%ZIF]Z;P,9&T=M M./IW]I9W[E%A7G(P<"M()HN#D6!DH@HH5/WT0.M,KXH,.\2MY^-'BEQ0V#7./MRLD?Q[:<@[-'6&=F6=XL$O:]?G MT8$H05#AY=D-CG47[=RT0CDD&P"H5,YSB;Q45ZNN8\>\I4)"Q]'?&5U7XW[A99^SKQC&C3\M$JK:Y,/09F3\80\@9(2>)_`I?2T\C>.\Q>>3K MK$<8M8'6XE+10P/#2*-$C#&5%:ENHK7][LK7I6NJWQIY+PEGXLMAD>DWJ/5EL MZJV\Y5<\A>:1'(I>\JO175MCFD=/N"(]C_2D6*\["']%W].L7EO&O)<5BYUAR\ M>+D:M$TD"K/'BYUE3`7R45.8YA$QA$6!Y"FFG\."K$DT$@`%3UH M``!]@``Z:6WC6&&W\V\UB@14B`L^B@**F.I-!0=223]I))ZG5SU_*4]#NY#E M*\G^\-=`90`XRY!Z MCL2?[AUR=?#W>[#P@U+CC3;G+.E^/GR496RM-'E'H`G'U7D15)N5K*]>*IX` MDF:;;MT&GI]I;Z^.\A'VC==A>:L?;\^Q.3OK%`.1\7NS'*H^:2SD19-_^R26 M^[9+3U&N*/!.0N?'67Q=A?R,W&>5V@>)CT6.\C=H]G^U0(?B>Y#7Y3K5_F,M M4SR(T.D[TA)K&QG*>6M?XD8U'%.48JUSM=;.K'ONC^(^:+IL:\1S*N,UB&]M M1.%7'U[^DOPG9P<:QL_'64?GEYAWR-RWZ4:.0EI#]H/:+3,/4&5=0O.]Y<YAH40E#Q$8DF<# MY)9<:CY?<)!^0RE0D@GA8LS?H!%_Y1)PNV>X_ MO#"&+Q&WG4*J`$N7:,)L-5VONVMN7:3N%=>E?D*XJUU[N#.VWJ=I1..96P:_ M)73/+]5X:KO)-R@VK\0E+S%<:L)V=M8.2+1#%@=RZDVQ@6;IJ)?;ZDQ>-N77 M,=@]G;QSG)U^F6*:&1I`H)=MJN2B1T(D=PJHWM8@]-19?*7"[:7(Q7EQ+!^5 M4^I,L$\:QEB`BAFC`=Y*@Q(A9I%]R`KUUA,R^1_C+I5[0S1P^T;*[O*TY_H5 M4@-ORVYY2ZO='BV3B3D+-2!M$8V2L+)K&M%7!DDC`[]E,Y@2[$-VD97QARK% MX\Y55M;NP2<0R/:SQ7`BE8A0DO;8["6(%3[:D"O4:\,1Y7XCEL@,4[7=E?O` MTT:7=O+;F:)5+%XNXH#C:K-0>X@$@=#2,H#YA^!%KL\!5*MJ=AL7=I'%%%:]\AIX@=HK55&_W2`"I5:TW*":L`:BU\[^-+V\CLK.\EEEDNOIP5 M@F*[CM`9CL]L;%J*Q`KM<@;49AM%;^4GBK;9>K-X%76WM.O>J1^,T78C8Y>6 MV+7&_24[^S:,9!:2ZC$8%5L67`4OJ%3(HJ"`^T*@@(=1;KQ+RZSAF:X^C6^M M[1KF6V^IB-U%"J;RSP!BX.WK05(^--2[3S+PN]GA6V-\UAM*T.GATNL2-USG0:9$2IH*6MU(ME7BYP@JE/#2,_`OXIE M*D,CV6*:/GKU@<5=Q6&4MKZ=.Y##<1R,GZRHX8K]GN`I_/IBY MBSER.)NL?`_:GGMI(U?]1G1E#=.OM)KT^S7,Q\8_)O.N%$=8/BVY]9;$8W;% M+;90B+K<(A@[R_7&%T?'!%O:9AZV-'.F,EY^Q%RZHJQ;IE[:"IVRR/@IU1Y4 MXKD^=21>6?'5V]]9B%-T4;$3VYB'4QJ#N!7UDC%)%:K`,&J.1O$G+\3P%)O$ M'DNR2PO#/)MEE4&WN%E/02,1M*D>V.4UC9`%)0KUN[E;MQ1^,7CI2:M-6A]3 M,KB9J1K675A0\S?+C/R]LGI6SMJ71H6-;/[#8Q;.)=1-F@DFH#9H5(AS@``8 M4-#8'$+(R6Z$M-*[2NTG;B4`N]"QVCT5:5/QUH%3^4OC1;-8K^)J16S4?1I2" MN=QGJ[JF2VC-']'HE)ITA5ZLJX`P&(0I#&"QO M/$G*;/#R9T/8W&,22*-'M[B.<2RRR+$(D,9(#J6!;?M`'H233559>9>)7N:B MP!CR%ODWCEE=+BVD@,,,432F602`'8P4A-F\DUJ`!74F4SY">)EZP.^\GX73 M11PO.+?,TBPWR4K5ECVIYJ%"*]XT5%*Q1IV29/#3+P;>NTA>M?32D1EEMCFG:%I]-TCCA% MQ#2[0=KLEI3ERUUB+^)A6XJ-H8%9(`>E>G0$B/VDSE.'6QX9@?)_&%R7*)9S9W5TDUDJB M19)'![9JJCHGN]VX@TZJ:TU!.TV:LY)\Z%,OKFLS+Q!'@O8I.7C<[I,E:KC: M)=W<):(:?2UVJQSN:L4RX$4$`4,0PIHD`5%"(IB)=#@[2[S/@&?')*BDY]55 MII5CCC41HQJ\C!44=32O4GH"QZY?/WEE@OXBH+,L$+22R,9)5%$C M4L[GVBOP`ZD*.CVN(C'-"XAD*% MXI!4>Y2585HR^H8:5[@1STP;C+P$X;U[9T=2JE>4SZM0DGK9LFO+W%Z[-6B; MFEH:,GM*:Q*D"V5>0\W$2)1DDC#)42* M8U"EM(F[X6;;D=['<127]L[FX2)#%%.(9#[C"=@CF,4E5>.0I)1HV$K%PFM? MM.48=+4J?N>0U&_-ZG64'J5AU#3&PUB'B;"S?C"JTNHT>2KD3;+]H2=E(:), MU,$;$-Y+^C4?*'(9`95IF.00WT=CFI[<2?N]O[N)9.AD)! M72IMZ]K?[/YQ"Z!;V;7)JA(5J2@9IQ1J<=V+;3XRU2TW*71*'K\2Y3KMK3B3 MR\::*&/>-XF+\1,NY>%2/KVN<-]3=7&-@8YB975U$LM*P-&JK%N=AOCW"-^Y MO4R25]JH6&)6USOTEI;Y6=5P<#1LCF&*M+A9&=I@B*>W*$[L9BV.L4=*L\@4 MNJIB&(0#IG3+KCFRH:[,INCTZH49]"7"IZ2W9^Q]9.TG1UJ[#UMC78U-XW4? MGL!X5W'IKD$Z)P.D97"C/Y^X1KZPOK$X6,CN22AHY(":T26`.SEVH0@A$JN0 M:,*$!AGCO'+5UQ^0Q]^,[(#VHH2DL5P!2KPW!C2-8UJIY"N[_<]!._9Q->SZO.:"6EP(Q,_",K_`&$S"6G8\U^=UN*L5GD*972M6[]5 MJG&1@R,@H@5N=1D=0:KF7)(KGCD&."L]STFUT$[[6=>\8U>1HDVJY41Q]QRH0F,G5G M_D4@"'M>+ M=W)N_P"QWM%SX^CK4>**JW5!E_[,:=_;8JY^Q/M@X)(>/I[W5YDWN/\`)/CJ M\IW?GQRT7TO<_&[(E:AZ^[;VJ#KTVF*OZ.J#%):_YY\E;B5!Q]<1-]7VOP.Z M85W#I[-W?W'I^D)J?IZL3^"*+C&OQE\?G39BS2MA>+:<7MVN8CU#6K.4DK^E0,5-5#;:;F!4,-*/@^$XSR? MQS?\:Y'=FR:]Y5,EI*/5;L0HT=#\M2H<48KNKM5@Y4B8Z7L_)NEDY[\#>82U M/U[5LEX)ZU=LYY-UR/;EM5DR1]65VZ5:O3WV"21%Y!R[0=%*OX+F*:Q=CVTN`]=\0KM]H!6HJNUAMV>Y!>Y M;CTY+XXYQV+[-67'+J6"_11W'MC'^'*U`WN+*U&HVY3N,E5@NV8X'5=+4'0UI!5)2NP5HD+HW+2Y.UD.8S=JS`(YZ"*KCLF4J#@.X?;#K M9;))>1^1K3'*W]XIK4=FGSL@A/=6/XD^Y*@=:E/NUCF=8N.^-KS)LO\`=J&\ M?O[NJ)(;E3&TGP``20U;H%5_@#JR;YRW#:?C>"-*H"I7_(N:YA4":QUG"JD6 ML[>-9-W9;!-LBMC&=H0:4@K&&77``1[IE,8>R8B"O\!(UO+R"^R0V\:CPLRW M);I&6)&Q37IO*B2@]>I`]=-3^(AUN8N.V&+.[E#YJ)[8)UD"@$,XIUV=PPDG MTJ`3\M1\O&IG?9+Y.?F4895.URMZ.[J>!MZ5/VR*<6"M0]E/1UR1K^=A6+MD M\DHULZ$!51353.8OIW#KTY2^.B\5<(DR\/$$R4OE_GD>&DBBRABLQ$\BED5^UT+*""0#Z@:>#/*9\@U;/=Y/DYN_'"_9 M@3,KPFI!YKD]EI%D)/&B3&C)$T],6:18I1;1$B_OIF2[G\RB`E["/6!R-]XX MNOIXN*X_)V^5^KB]TTZ2ILW>Y=BH#N/2AKID8ZQ\E6BW,W+6<)R\[/A0XD4&J6*)I^NT:(87S(+^]6>)(U2WPUY ML2+]%T_ADG,LR:R,0LLF?V"BHFZ3;J]O)$O9FY?G?^7_`)TS.1O(GFPUPYBN M(0`>Y&T2%2`U%)#`'J:%2PK[M*C#^/AY&\`X7&V-U3CEPV^/3$ZJL48;/.1=+AP?.E"D>SD@E6IUW9 M;5(BJH915_8;`]YO6V\'YR\Y/S?DF>O!^_N<;(U!Z(#(@2 M-?L"(`BC]5>FJ7SU@++BG`N,<>LC^XMSB9)A/)QO"H`Z7G,/T0ZQ(J85;)>)7RM7FW2PMQ,;[;I= MH4!`"AUC/%)7F'',OXINV47%RGU=B6-`EU#3VD%I?!`"7M9B0K??L+-MZ]7,0KTTA/."K6R`XU\*N0VP1[QK4=[^ M0&OKEG\BJ>Q#T;(HMK$^"X"FBY(<`#S4[&8G`[NS MN.4YWC6%93>8[CKV%B1\SO%7ZAX_VI;EC)4=2M/@-+/R!97]MQ+`/;*[7%M$),E<3K6>01?-N0$QVL*&JA02[5H7J:%SV_'$N^36'./)%_ M9ME1-VL9;6[4MXS*:KL-6 MMB6^I;"68B%:#N.Y`]?:"6"U)Z=!7TUDO!`QT&`Y5=Y!5^D7.WAE-*GMI&I; MTJQHI>@'7J:=3I8F#2^_&!)8#8\9T:K(_7(*)D*`O&?BZ:MGHD=CJI'Q_E>+(VV2!Y3 MW$:(L"2RD;P12KK22-)")-=(NUZK!X7DNC['9XR?FJ[F-0G+M.QE69(2-A>1 M-?9*2$@2)9.G;!NY=E:HF,!3K)E[%'N8.N8,%B+CD&9M<):/&ES=3+$C2$J@ M9S0;B`2!7[`==7\AS5MQS"76>O$DDM+.!Y76,!G*H-S;02H)H*]2!]^J\>:M M?X/<].!]RUJV6B@SM$BLRL5^SC8$).*:V'/+$T@'$E')-GYU0?L))22139R, M"O\`:=J"+91'WO`2LK@ESS[Q[Y!@PUG%<1W[W20S6Q5BDR%PI)'H5VDLDP^4 M>X-MK56>0;;QWY)\;SYR]FMGL$LWF@N0RB2"0(64`UW!MP"O">K'V%=U*4.\ M5;;I5IT#X)+?R3=RB^?,Y'?ZQG-@MZJ_T3N5@Y^0C\U4=O)$?;._2]F):1:I MS>XJW:-Q()@+Y==!\NL\7:8WR!9\75!DF6TDF2.E0KH#/0+UI0RLX]`6:M-< MY<.N\O=93QY>2WBDD1 M[;',"H)!5)69R".E%'5C\!U/32\X'?65KX,Y9%_Y/Q]6&`J? M-/,O_P"9>?ZH=0.1_P#A#A)'_P"M:_ZKG3[6V=@U_P#4"Y2T0FHA=VUX26B& M=-4)-DJY:S!I^PRA(AT@FN95M*&C#`Y!N<"K"W$%0+X"!NEY:6]PO\.EV[1N M$.=1@2IH5V1KN!IU7=[:CINZ5KIC7ES;-_$U:1K)&7&!92`P)#;IFVD5J&V^ M[:>NWK2FE1T67A9CY`_F3T>K2T2VS&K\!9+,]`LP/FC6M.=1+/"E"7%NLSLSA?4 M)1E:M*4(/IUUBLQ/!/Y(YWE;-T7#P\:D@F>H$9N&@A5$W?*9-R.@%:[E9?7I MK,V2VT>+_P!-?76]BDHE8]@Q&!IU;8*.&Z[F2OB^J$+%1$:V`QE5YIB]:F6, MB0!52*W.80`"CVCVMG?R_P`3\K6RN!'?-(YH0%B%O[F8^@4@TJ>A+`?'4^\O ML='_``L1K*=)N!_Z-*519.#?H`$.:<%=P1RR8V^;;C;Q1&Y/I&P-8IO\` MI/U/Q,9D7]+75/(K.XD@CRF.7=E;)S)&H]9$(I+!_P!5*A:]!((V/RZJ90V& MC;>TI6=%LZS7&XS4=COEW?-T'KB;M;R:U^ZO8NEUZ"C47%AE[.6&G$8\L>R1 M7>DD9998B958=02N-L)D,"\^3[0.;>TMH8@2`D86VB#2N[$(L>Y"^]R%*1A2 M:3C2.7/XWD26^)[Q&`2\NIIB`2\I>ZE*Q(B@R-)L<($0,XDD9@`T!HU]G:2L ML&OS.I8G<:/BFO5JAPM?G(Q&.L]ORQ7.&TL>OV^^9O7"NY"KQ:+QXW>M/H3R MWW>5GXR:;,IC%+D+5X8?HH,3?P7&=LI9F=&)CCG[Y7?'%,]!(Q`*MO$>_=6( MN:5V]ZD\XO[C-8ZXMN/7\,*(ZA9);8P!MDLUO'5HU!*NNPR[`M)A&*T6_.>0 MD\PL&,98Q=15BUZIQ.RYMDGT#TLY7K2A/H4)K59E*4:JK$DJEG[5FN[>+`85 M/V;:,W!Q]UV'6GR?&[>2VO\`+R!XL+,]M/<5&QXRAF,BE2!MDF)"J/3OLZ@4 M361Q/*KJ.ZQ^%C*2YZ!+JWMMIWQR!Q"(W#`G=%``S.?7Z=8V/N?5O&.'KDP>@K+F[=@[`"6 MRF0ERE_)?2@*7/11\J(`%1%_91`%7[@-/G$8R'#XZ+'PDL(Q[G/S.[$L\C?: MTCEG;[R=;M_M_((?D'\H#U`U8Z1BZ?&?P/OUHD+K8.,V?MK5+*.%92;J0SV? MO)-1X;S>'D!H4S6TWHO#^JWN%-[H^INX],"Q\J>0L=:+8V^5N3:(`%639,%I MZ4[JO2GPIZ?#2XR'B+QMD[MK^ZQ%L+MR2S1;X"Q/J6[+Q@U^-1U^.I9JW$+C M'1\DL&$T[$J#6,DMA`):J5!Q`1L?9NRB2ON6%VU53E9IP8R)0,JY<*J&*'B( MB41`::[YIRN_S,?(+V_N).46V9EEN45:B4"\IO$K74 MZXB\CX>7)(,%(M[[C=-X(MC.F*IDSF0%(QN_<1\O7KSRG+N29O(0Y7+7DUQD M;OM6$@VC)"PUU*21A9IRV0D2%4DH].7< M`17\\?<[F$1*7QN3Y/Y^UVE^V5NC>1QLBN2I8(Y4LH)7T)5>GW=/CJC7Q/XY M2T>P3$6JV,/8K!:Y";G92&*Q<'2(T5;U;="!M18VJ#N1(PB*U0#N"[B?4ZM<'P/B''(+BWPUA#%'=KMF)W2- M*I!7:[R,[LM"1M+;:'TUJ%%^/WA=FU$O694[CEF["AZ8FS1O59D(US9&%B;Q MJ[IU%M70V5Y+N$&<2\>K+M$4#I)M5U#*)%(<1-U-R'D?G.4R%OE+W)W39"UK MVG#!"A8`,1L"@E@`&)!+``&HZ:A8[QCP'$X^YQ=CBK5;"\IWD8&0/M)9:F0L M0%8EE`("L2RT/763QK@UQ+X_VP+[DN(52L79.,-"LK:Z7G+58X>&,`D-$5^8 MN$M/OJY%F2,)!;L3MTA3$2B7Q$0Z\LYY`YER.S_+LQ?S2V!;<8P$C1F_6=8U M0.WQJX8UZUKKTP'CCA'%[W\RP>.AAR`3:)"7D=5_51I6*O51D/JS*"(^\!_#^; MX^G4?)\WY7F,8N%RE]/-BDV[8F(V+L^7:*=*?=_/J3BN!4&: MDH6JM%&4F;'65(18S=`I1\/$![=Q#OZ]3<[R7.\GN4O,_=2W=TB M;5:0U(6I-*T'2I.H/'^+\?XK;/9\=M(K2UD?>RQ@@%J4K2IZT&M.VOASQ=Y' M3T79]UQ"AZE/PD5]R1,G;HQ217CXKZE9Y]&U`7!$DDQW;J= M@>;\MXQ;O:M[3C/\`'MC6.S[#`]#LD`^W6Y1E;>+9KG/'[*Y1O;%\ M]+8G9%V3.T:+,0:$DHOQ(4C)U M%/$56BB*/ME%/[/=(Y"F((&*`@K;+(W^-O4R6/FEAR$;;ED1BKJWVA@:U^W[ M>H/KIMW^,QV4L'Q>1@BGQLJ;6B=0R,OV%2*4'2GV$`BA&EHS+X_^&V./GTGG M.!4^`DGT#,5WMJ.FMRR7A_QDPA.WH8_B]+SU"_19X6YH5QHZ M:(66-5*L15O*HF=JI.3JD<'`RH@"I@,(";MU!S/->5\@,+9J^GN6MWW1%R"4 M;IU7IT]!T]/NU/PG!.(<<$ZX.P@MEN8]DH0$"1>O1A4U]3U]?OU'F=_'3PDR MBWU>]Y_QUH]?LU(6^KIKD%)^3C:K(^T5$9FO5V9F9"NQ$^8LI<=D MGXEUY_32D+-,EXZ4CW'MG(I[+QDY.F;Q,4WB8>P@/6,M;F>RN8[RU8I) MF:%")3CDVS$IK(2&NMCF>)\:Y!B5P>8LK>?$I39$5HJ;11>WMVF.@Z`H5('3TU2Z]Q M6#POY<.+,CB?'+8(#C[EF-7[-[5<*WEVCV"E-=%T]:RNVDBZN;YO+.;`T6"; M9ED)<[EP@U$!*JJ4$3^#S3.W'(/#F63.Y.RDY'=WL4\<;W$"2F&#M@J(@5"$ M;&V1A06]0/<*H)\#:\:\U8EN/XJ_BXU9V]VQQ(/++-/JZ5PA-2$HBX0D)5_"'6&`6 MF7172AC//I?JO<4,H"@'$3=*:W\E<]M<;'B;?*WB8^$`(H>A4+0A0_SA10>W M=MH`*4Z:<%SXM\>7F3DS%UB+*3(3%B[,E0S-713`\B+=DX=&:)B)TRE$H@ M/CV\C=_N/R;SZ*[DOH\I=+>3*JNX*AG"UVACMJ0*GU_]M?$GBKQW-:1V$N)M M6LH69D0ABJ%Z;BHW4!-!7_YU[T;XZ^$FL2\58KWQSH4I9H:-BHAA:H\)JL6P ML?!QZ$3$HN[15I:%GY([",;)MTU'+E54$B`7R$`[=?F,\F<\P\+VV/R=PEJ[ MLQC.V2.KDLQ$22^#5O"LT88_8E%'%CH"M8824%9'BBR3@TE8R2 MB;US/RX+MTU"O'BBSDITB&*H`D*(5=WS/E=]F4Y#WD3:]-B,Z_JM(BK(R_:I8@_$:H\=XC\ M<8F]3(V.)MUNHVW)4R.J-THRQN[1JPH*$*"*"GIIZ.X_E_'W_P"/Y>E_IC:` M_"'^\/\`MZ-&N:6V_P"=NX?JS]U[3_D\_>?_`!7U']4?V_\`B[_Y_P"NZZFL M_P#`4/S_`(T?_>C1H MZ-&CHT:.C1HZ-&CHT:.C1KW^+^?^#_A_W=&C7CHT:.C1HZ-&CHT:.C1HZ-&O "_]D_ ` end